Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Actinium Pharmaceuticals (ATNM) Notes Payables (2021 - 2024)

Actinium Pharmaceuticals (ATNM) has disclosed Notes Payables for 6 consecutive years, with $7.5 million as the latest value for Q1 2024.

  • On a quarterly basis, Notes Payables rose 2.11% to $7.5 million in Q1 2024 year-over-year; TTM through Mar 2024 was $7.5 million, a 2.11% increase, with the full-year FY2023 number at $8.0 million, down 21.49% from a year prior.
  • Notes Payables was $7.5 million for Q1 2024 at Actinium Pharmaceuticals, down from $8.0 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $10.1 million in Q4 2022 to a low of $3.4 million in Q2 2021.
  • A 4-year average of $6.5 million and a median of $7.4 million in 2023 define the central range for Notes Payables.
  • Peak YoY movement for Notes Payables: surged 108.56% in 2022, then dropped 21.49% in 2023.
  • Actinium Pharmaceuticals' Notes Payables stood at $5.5 million in 2021, then skyrocketed by 83.02% to $10.1 million in 2022, then dropped by 21.49% to $8.0 million in 2023, then decreased by 5.53% to $7.5 million in 2024.
  • Per Business Quant, the three most recent readings for ATNM's Notes Payables are $7.5 million (Q1 2024), $8.0 million (Q4 2023), and $8.2 million (Q3 2023).